Introduction
Nonsteroid anti-inflammatory drugs (NSAIDs) and lowdose aspirin have emerged as the most important cause of peptic ulcer complications in many developed countries where the incidence of Helicobacter pylori-related ulcer is rapidly declining. The conventional approach to preventing peptic ulcer complications associated with NSAIDs and low-dose aspirin is identifying gastrointestinal risk factors and co-prescribing gastroprotective or less ulcerogenic drugs. Cyclooxygenase-2 (COX-2)-selective NSAIDs offer the hope of minimizing gastrointestinal toxicity while preserving their therapeutic effects. However, the enthusiasm for COX-2-selective NSAIDs has markedly decreased after the withdrawal of rofecoxib due to its cardiotoxicity. Subsequently, there are data to suggest that not only COX-2-selective NSAIDs but also many nonselective NSAIDs increase the risk of myocardial infarction. Nowadays, clinicians often face a dilemma in prescribing this class of drugs. Unlike NSAIDs, the prescription of low-dose aspirin and other antiplatelet drugs is rising. With increasing use of dual antiplatelet therapy in coronary intervention, bleeding complications are expected to increase. Although proton pump inhibitors (PPIs) may reduce the risk of upper gastrointestinal bleeding associated with dual antiplatelet therapy, recent data suggest that PPIs may have an adverse interaction with clopidogrel. Prevention of bleeding complications in cardiac patients becomes a new therapeutic challenge. This brief review selected research articles published in recent years that sought to address the above issues.
Magnitude of risk
Many studies have reported secular trends of upper gastrointestinal bleeding in different geographic regions. Few studies, however, focused on the changing epidemiology of gastrointestinal complications associated with NSAIDs or low-dose aspirin. In a Danish study, the proportion of NSAID-related peptic ulcer increased from 39% in 1993 to 53% in 2002, although the absolute incidence remained static [1] . In Scotland, however, the annual incidence of upper gastrointestinal bleeding rose significantly from 98.7 in 2002 to 143 per 100 000 in 2005. The rise in the incidence was associated with a 44%
Although the overall mortality of ulcer bleeding or perforation has decreased in the last decade, deaths associated with NSAID-related ulcer complications have actually increased. A systematic review of published data from 1966 to 1996 reported that the mortality risk of more than 2 months of NSAID exposure was 12% in 11 000 cases of gastrointestinal bleeding [4] . Recently, another systematic review compared the mortality data of studies published before and since 1997. Of the 61 067 patients analyzed, 5001 died. The mortality rate in all cases fell significantly from 11.6% in pre-1997 studies to 7.4% in those published since 1997. In contrast, among 5526 patients taking NSAIDs or aspirin, mortality increased from 14.7% before 1997 to 20.9% since 1997 [5 ]. However, one should interpret these findings with caution because there were substantial differences in mortality rates between different study designs. For example, randomized trials reported low mortality rates that could be explained by selective exclusion of patients with multiple comorbidities. Furthermore, the causal relationship between death and gastrointestinal complication was rarely examined. Nevertheless, poor adherence to guidelines on the use of gastroprotective strategies for high-risk users probably accounts for the persistently high incidence and mortality of ulcer complications. In a nationwide study in Sweden, Johnell and Fastbom [6] found that gastroprotective agents were only used in 22% of NSAID elderly users, and concomitant usage of other drugs (e.g. corticosteroid, warfarin, aspirin, selective serotonin reuptake inhibitor or multiple NSAIDs) did not increase the likelihood of prescribing gastroprotective drugs.
Treatment of nonsteroid anti-inflammatory drug-associated ulcers
Among patients who develop gastroduodenal ulcers while on NSAIDs, PPIs are generally thought to be the standard therapy. Provided that NSAIDs can be discontinued, however, an old study actually showed that over 90% of gastric or duodenal ulcers healed with 8 weeks of a standard dose of ranitidine [7] . A more relevant question is whether PPIs are superior to histamine 2 -receptor antagonists (H 2 RAs) in healing ulcers among patients receiving continuous NSAID therapy.
In an 8-week, randomized trial of two doses and esomeprazole (20 and 40 mg) versus ranitidine (150 mg twice daily) in healing gastric ulcers associated with continuous NSAID therapy, surprisingly there was no significant difference in gastric ulcer healing rates between the groups receiving esomeprazole 40 mg (85.7%), esomeprazole 20 mg (84.8%) and ranitidine (76.3%) [8] . Unlike gastroesophageal reflux disease in which acid suppression clearly shows a dose-response relationship, such an effect has not been demonstrated in healing of NSAID-associated gastric ulcers. It is likely that factors other than acid suppression also contribute to ulcer healing.
Prevention of nonsteroid anti-inflammatory drug-associated ulcers Systematic reviews of randomized placebo controlled trials have consistently shown that PPIs, misoprostol (400-800 mg per day), double-dose H 2 RAs (e.g. famotidine 40 mg twice daily) and COX-2-selective NSAIDs significantly reduce the risk of NSAID-associated endoscopic ulcers [9] [10] [11] . To date, however, the efficacy of PPIs in preventing NSAID-associated ulcer complications has never been documented by placebo-controlled trials. Nevertheless, a number of observational studies have consistently shown that PPIs reduce the risk of ulcer bleeding among NSAID users. In a multicenter Spanish study, PPI co-therapy reduced the risk of NSAID-associated ulcer bleeding by more than 60% [12] . In a Tennessee Medicaid database, concurrent users of NSAIDs and PPIs achieved a 54% risk reduction, but further risk reduction was not observed among concurrent users of PPIs and coxibs (risk reduction 50%) [13] . In the Manitoba Population Health Research Database, cotherapy with PPIs or misoprostol or use of a COX-2-selective NSAID significantly reduced the risk of ulcer complications. There was no significant difference in risk reduction achieved by COX-2-selective NSAIDs alone and NSAIDs and a PPI [odds ratio 0.75, 95% confidence interval (CI) 0.53-1.06; P ¼ 0.1], although COX-2-selective NSAIDs were superior to low-dose misoprostol (400 mg per day) (odd ratios 0.68, 95% CI 0.56-0.85, P ¼ 0.0006) [14 ] . These findings are consistent with those reported by head-to-head randomized trials [15, 16] .
Current evidence indicates that the combination of a COX-2-selective NSAID and a PPI provides the best gastric protection in high-risk NSAID users. In a 13-month, double-blind, randomized trial comparing celecoxib versus celecoxib plus esomeprazole in patients with prior ulcer bleeding, recurrent ulcer bleeding occurred in 8.9% of the celecoxib-alone group compared with none in the celecoxib plus esomeprazole group (P < 0.001) [17] . Two Canadian population-based databases found that a COX-2-selective NSAID plus a PPI achieved the greatest risk reduction for NSAIDassociated ulcer complications. In a Quebec retrospective cohort study, the adjusted hazard ratio was 0.69 (95% CI 0.52-0.93) for celecoxib plus PPI versus celecoxib. Subgroup analysis showed that use of a PPI plus celecoxib may be beneficial in patients aged 75 years or above [18] .
The Manitoba database also found that the combination of a COX-2-selective NSAID and a PPI achieved the greatest risk reduction (versus NSAID plus PPI: odds ratio 0.53, 95% CI 0.36-0.79, P ¼ 0.0018; versus COX-2-selective NSAID alone: odds ratio 0.70, 95% CI 0.55-0.91, P ¼ 0.0068) [14 ] .
Although PPI co-therapy is a commonly recommended strategy for high-risk patients, whether primary prevention is cost-effective in average-risk NSAID users remains unclear. Two economic analyses based on hypothetical modeling suggest that prophylaxis with an H 2 RA may be cost-effective in average-risk NSAID users [19, 20] . Interestingly, a recent study suggests that testand-treat H. pylori infection is potentially the most costeffective strategy even if H. pylori prevalence is as low as 5% [9] . One should be cautious that many economic analyses are based on the assumption that the same relative reduction in endoscopic ulcers would apply to ulcer bleeding. Clinical outcome trials are needed to validate economic models in the primary prevention of NSAID-associated ulcer complications.
Cardiovascular risk of nonsteroid anti-inflammatory drugs
The 'COX-1/COX-2 imbalance hypothesis' was once thought to account for the cardiovascular toxicity of COX-2-selective NSAIDs. However, the fact that both COX-2-selective and nonselective NSAIDs increase the risk of myocardial infarction suggests that the mechanism of cardiovascular toxicity is more complex than unopposed COX-2 inhibition. In a pooled analysis of six placebo-controlled trials of celecoxib, the risk of serious cardiovascular effects increased with the dose of celecoxib among patients with high baseline cardiovascular risk [400 mg daily (hazard ratio 1.1, 95% CI 0.6-2.0), 200 mg twice daily (hazard ratio 1.8, 95% CI 1.1-3.1) and 400 mg twice daily (hazard ratio 3.1, 95% CI 1.5-6.1)]. Furthermore, celecoxib was associated with increased risk regardless of the baseline aspirin use. These findings suggest that other factors such as dose, duration of therapy and patient's baseline cardiovascular risks contribute to adverse cardiovascular outcomes [21 ] . Current evidence indicates that naproxen does not increase the risk of myocardial infarction and is the preferred NSAID in patients with increased cardiovascular risk [22, 23] .
Balancing gastrointestinal and cardiovascular risks of nonsteroid anti-inflammatory drugs
Recently, there were updated working party reports that sought to provide recommendations on the use of NSAIDs according to patients' gastrointestinal and cardiovascular risks [24,25 ,26] . Overall, the initial choice of an NSAID relates to a patient's cardiovascular risk (i.e. naproxen versus nonnaproxen NSAIDs), and the use of gastroprotective strategy is determined by severity and number of gastrointestinal risk factors (Table 1) .
Low cardiovascular risk
These patients should be managed according to their gastrointestinal risk. Briefly, patients with low gastrointestinal risk should receive the least ulcerogenic NSAID at the lowest effective dose. Patients with high gastrointestinal risk should be treated with NSAID plus PPI or misoprostol, or a COX-2-selective NSAID as an alternative. Those with a history of ulcer bleeding or multiple risk factors should receive a COX-2-selective NSAID plus a PPI or misoprostol.
High cardiovascular risk
Cardiovascular risk is defined as 'high' if a patient requires aspirin for secondary prevention of cardiovascular event. The role of aspirin for primary prevention remains controversial. If NSAIDs are deemed necessary, naproxen is preferred. PPI or misoprostol should be prescribed, as concomitant use of naproxen and aspirin will markedly increase the risk of gastrointestinal bleeding even in the absence of other risk factors. Patients with both high cardiovascular and gastrointestinal risks should best avoid any NSAID or coxib. Other form of analgesics (e.g. acetaminophen) or even short course of corticosteroid should be used instead (e.g. to control arthritis).
Management of patients on antiplatelet therapy with high gastrointestinal risk
The American Heart Association and the American College of Cardiology used to recommend clopidogrel as an alternative to aspirin in patients with acute coronary syndromes who had major gastrointestinal intolerance [27] . Now, there is good evidence from head-to-head randomized trials that combination of aspirin and a PPI is superior to clopidogrel alone in patients with prior ulcer bleeding [28, 29] . Recently, an updated consensus report recommends PPI co-therapy instead of switching to clopidogrel in aspirin users with high gastrointestinal risk. In addition, the consensus document recommends prophylactic PPI in patients receiving dual antiplatelet therapy [30 ] . However, an in-vitro study suggests that some PPIs may reduce the antiplatelet activity of clopidogrel by inhibiting CYP2C19, a hepatic cytochrome P450 enzyme [31] . Recently, two observational studies reported that the risk of myocardial infarction was significantly increased among concurrent users of clopidogrel and PPIs [32, 33] . This finding, however, should be interpreted with caution because imbalance in baseline cardiovascular risk factors existed between the cohorts with and without PPI co-therapy. Prospective trials are required to determine whether there is any clinically important interaction between clopidogrel and PPIs.
Conclusion
The growing usage of NSAIDs and low-dose aspirin has imposed significant burden on our healthcare system. Of the various gastroprotective regimens, current evidence suggests that the combination of a PPI and COX-2-selective NSAID provides the best gastric protection. Before prescribing, physicians should first select an NSAID according to individual patients' cardiovascular risk (i.e. naproxen versus a nonnaproxen NSAID). Requirement of gastroprotective therapy in NSAID users will then depend on the number and nature (e.g. prior ulcer bleeding) of gastrointestinal risk factors. PPI cotherapy is recommended in patients with high gastrointestinal risk on aspirin. Whether the potential interaction between PPIs and clopidogrel will translate into clinically important outcomes remains uncertain.
